Free Trial
NASDAQ:MDWD

MediWound (MDWD) Stock Price, News & Analysis

MediWound logo
$14.97 -1.03 (-6.44%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MediWound Stock (NASDAQ:MDWD)

Key Stats

Today's Range
$14.76
$15.60
50-Day Range
$15.52
$20.33
52-Week Range
$12.78
$24.00
Volume
51,063 shs
Average Volume
89,747 shs
Market Capitalization
$161.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.33
Consensus Rating
Buy

Company Overview

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Remove Ads

MediWound Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

MDWD MarketRank™: 

MediWound scored higher than 28% of companies evaluated by MarketBeat, and ranked 801st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MediWound has only been the subject of 2 research reports in the past 90 days.

  • Read more about MediWound's stock forecast and price target.
  • Earnings Growth

    Earnings for MediWound are expected to grow in the coming year, from ($2.66) to ($2.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MediWound is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MediWound is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MediWound has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about MediWound's valuation and earnings.
  • Percentage of Shares Shorted

    12.02% of the float of MediWound has been sold short.
  • Short Interest Ratio / Days to Cover

    MediWound has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MediWound has recently decreased by 2.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    MediWound does not currently pay a dividend.

  • Dividend Growth

    MediWound does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.02% of the float of MediWound has been sold short.
  • Short Interest Ratio / Days to Cover

    MediWound has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MediWound has recently decreased by 2.85%, indicating that investor sentiment is improving.
    • Insider Buying vs. Insider Selling

      In the past three months, MediWound insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.20% of the stock of MediWound is held by insiders.

    • Percentage Held by Institutions

      46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about MediWound's insider trading history.
    Receive MDWD Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

    MDWD Stock News Headlines

    MediWound reports Q4 EPS (36c), consensus (61c)
    MediWound files $125M mixed securities shelf
    DOGE Social Security bombshell?
    Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
    See More Headlines

    MDWD Stock Analysis - Frequently Asked Questions

    MediWound's stock was trading at $17.80 at the beginning of the year. Since then, MDWD stock has decreased by 15.8% and is now trading at $14.98.
    View the best growth stocks for 2025 here
    .

    MediWound Ltd. (NASDAQ:MDWD) posted its earnings results on Wednesday, March, 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.23. The biopharmaceutical company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative net margin of 142.29% and a negative trailing twelve-month return on equity of 82.17%.

    MediWound shares reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

    Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

    Company Calendar

    Last Earnings
    3/19/2025
    Today
    4/04/2025
    Next Earnings (Estimated)
    5/27/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Medicinals & botanicals
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:MDWD
    Employees
    80
    Year Founded
    2001

    Price Target and Rating

    Average Stock Price Target
    $31.33
    High Stock Price Target
    $39.00
    Low Stock Price Target
    $25.00
    Potential Upside/Downside
    +95.8%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    3 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-6,720,000.00
    Net Margins
    -142.29%
    Pretax Margin
    -141.46%

    Debt

    Sales & Book Value

    Annual Sales
    $20.22 million
    Price / Cash Flow
    N/A
    Book Value
    $3.43 per share
    Price / Book
    4.66

    Miscellaneous

    Free Float
    9,794,000
    Market Cap
    $172.69 million
    Optionable
    Optionable
    Beta
    0.82

    Social Links

    5G Stocks: The Path Forward is Profitable Cover

    Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

    Get This Free Report

    This page (NASDAQ:MDWD) was last updated on 4/4/2025 by MarketBeat.com Staff
    From Our Partners